Hostname: page-component-586b7cd67f-rcrh6 Total loading time: 0 Render date: 2024-11-28T16:41:50.978Z Has data issue: false hasContentIssue false
  • English
  • Français

Subcutaneous ketamine in the treatment of depression and suicide risk: case report.

Published online by Cambridge University Press:  19 July 2023

M. A. Cigognini  and
D. V. D. Meene
M. A. Cigognini*
Affiliation:
Psychiatry, Institute and Department of Psychiatry of Clinics Hospital of the University of São Paulo Medical School, São Paulo
D. V. D. Meene
Affiliation:
Psychiatry, Instituto de Neurosciência & Comportamento, Blumenau, Brazil
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Several studies have shown that ketamine, an NMDA receptor antagonist, represents a promising alternative in treating depression and suicide. The intranasal or intravenous use of ketamine, currently used, has limitations in terms of cost and complexity. The subcutaneous (SC) route may be an affordable alternative for the treatment of depression and suicidality.

Objectives

To evaluate the response of SC ketamine (0,5 mg/kg) applications on depressive, anxiety, and suicide symptoms.

Methods

A patient with unipolar depression and suicide attempt was submitted to 3 sessions of SC ketamine (0,5 mg/kg). The applications had 2 days of intervals. Clinical evaluations were measured by BDI, BSI, and BAI. The vital signs were monitored under 2 hours after injections and the potential side effects.

Results

Changes in measurement instruments according to applications can be seen in Tab 1:

BDIBSIBAI
Application 1261418
Application 2030000
Application 3020000

The average measurements of vital signs during 2 hours of monitoring for each application can be seen in Tab 2:

BPHRRFOXECG
Nine measurements (average)123/8078,8617,5599%NP

Conclusions

The use of SC ketamine showed remission in BDI, BSI and BAI, respectively demonstrated safety in use.

Disclosure of Interest

None Declared

Type
Abstract
Information
European Psychiatry , Volume 66 , Special Issue S1: Abstracts of the 31st European Congress of Psychiatry , March 2023 , pp. S1010 - S1011
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2023. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.